Vol. 2 No. 5 (2022)
Reimbursement Reviews

Daratumumab (Darzalex SC)

Published May 16, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses daratumumab (Darzalex), 1,800 mg/15 mL (120 mg/mL) for subcutaneous injection.
  • Indication: In combination with bortezomib, cyclophosphamide, and dexamethasone, for the treatment of adult patients with newly diagnosed light chain amyloidosis.